Burning Rock Announces Plan to Pursue An Alternative Listing
21 June 2022 - 3:59PM
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or
“Burning Rock”), a company focused on the application of next
generation sequencing (NGS) technology in the field of precision
oncology, today announced that the Board of Directors of the
Company (the “Board”) approved a motion to pursue an alternative
listing of the Company’s Class A ordinary shares on an
internationally recognized stock exchange. The alternative listing
is expected to offer fungibility with the company’s American
depositary shares (“ADSs”) that are currently listed on Nasdaq, in
order to ensure continued and seamless trading for shareholders
amid an evolving market and regulatory environment. The Board also
authorized the Company’s senior management to engage relevant
professional parties, proceed with the relevant preparatory work
and undertake the necessary procedures with respect to the
alternative listing.
The Company will make further announcements to disclose any
material updates and progress with respect to its alternative
listing in accordance with applicable laws and regulations as and
when appropriate. In the meantime, the Company will keep focused on
driving its sustainable business development as a Nasdaq-listed
company through the development of cutting-edge cancer diagnostic
solutions to maximize shareholder value.
This press release does not, and is not intended to, constitute
an offer to sell or a solicitation of an offer to purchase any of
the Company’s securities in the United States or elsewhere. It does
not, and is not intended to, constitute an offer, solicitation or
sale of any securities in any jurisdiction in which such an offer,
solicitation or sale would be unlawful. Any offers, solicitations
or offers to buy, or any sales of securities will be made in
accordance with the requirements of the Securities Act of 1933, as
amended, as well as other applicable laws and regulations.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to
guard life via science, focuses on the application of next
generation sequencing (NGS) technology in the field of precision
oncology. Its business consists of i) NGS-based therapy selection
testing for late-stage cancer patients, and ii) cancer early
detection, which has moved beyond proof-of-concept R&D into the
clinical validation stage.
For more information about Burning Rock, please visit:
ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute “forward-looking” statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates,” “target,”
“confident” and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports
to the SEC, in its annual report to shareholders, in press releases
and other written materials and in oral statements made by its
officers, directors or employees to third parties. Statements that
are not historical facts, including statements about Burning Rock’s
beliefs and expectations, are forward-looking statements. Such
statements are based upon management’s current expectations and
current market and operating conditions, and relate to events that
involve known or unknown risks, uncertainties and other factors,
all of which are difficult to predict and many of which are beyond
Burning Rock’s control. Forward-looking statements involve risks,
uncertainties and other factors that could cause actual results to
differ materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jul 2023 to Jul 2024